These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 36148493

  • 1. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhang N, Yu BR, Wang YX, Zhao YM, Zhou JM, Wang M, Wang LR, Lin ZH, Zhang T, Wang L.
    J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
    [Abstract] [Full Text] [Related]

  • 2. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B, Zuo B, Huang L, You X, Liu T, Hao J, Yuan C, Yang C, Yee Lau W, Zhang Y.
    Int Immunopharmacol; 2024 Aug 20; 137():112492. PubMed ID: 38906005
    [Abstract] [Full Text] [Related]

  • 3. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Wang Z, Lin D, Luo T.
    Ann Surg Oncol; 2024 Nov 20; 31(12):7860-7869. PubMed ID: 39090499
    [Abstract] [Full Text] [Related]

  • 4. Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
    Long T, Yang Z, Zeng H, Wu W, Hu Z, Yang Z, Hu D, Zhou Z, Chen M, Zhang Y.
    J Hepatocell Carcinoma; 2023 Nov 20; 10():1849-1859. PubMed ID: 37881221
    [Abstract] [Full Text] [Related]

  • 5. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
    He MR, Zheng ZK, Wu TQ, Chen MS, Zhou ZG.
    Zhonghua Wai Ke Za Zhi; 2024 Apr 01; 62(4):309-315. PubMed ID: 38432672
    [Abstract] [Full Text] [Related]

  • 6. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L.
    J Hepatocell Carcinoma; 2023 Apr 01; 10():1735-1748. PubMed ID: 37822726
    [Abstract] [Full Text] [Related]

  • 7. Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety.
    Liu D, Wang J, Ma Z, Zhang N, Zhao Y, Yang X, Wen Z, Xie H.
    Cardiovasc Intervent Radiol; 2022 Aug 01; 45(8):1092-1101. PubMed ID: 35588011
    [Abstract] [Full Text] [Related]

  • 8. First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma.
    Lin YS, Li S, Yang X, Guo RP, Huang YH, Bai KH, Weng J, Yun JP.
    J Cancer Res Clin Oncol; 2024 Jun 18; 150(6):309. PubMed ID: 38890157
    [Abstract] [Full Text] [Related]

  • 9. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
    Jiang N, Zhang Z, Yin X, Qiu H, Yan W, Hao Y, Yang W, Li H, Xu A, Mu K.
    Radiol Med; 2024 Apr 18; 129(4):631-642. PubMed ID: 38355907
    [Abstract] [Full Text] [Related]

  • 10. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z, Wang Y, Wu B, Liu Y, Wang Y, Ren Z, Yang X, Chen Q, Zhang Y.
    Front Immunol; 2023 Apr 18; 14():1235724. PubMed ID: 37720223
    [Abstract] [Full Text] [Related]

  • 11. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
    Luo L, Xiao Y, Zhu G, Huang A, Song S, Wang T, Ge X, Xie J, Deng W, Hu Z, Wen W, Mei H, Wan R, Shan R.
    Front Oncol; 2022 Apr 18; 12():1004652. PubMed ID: 36237309
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
    Yang XG, Sun YY, Li DS, Xu GH, Huang XQ.
    Front Immunol; 2022 Apr 18; 13():940009. PubMed ID: 35874708
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study.
    Dong Z, Sui C, Lu J, Guo J, Duan K, Wang K, Geng L, Dai B, Yang J.
    Front Immunol; 2024 Apr 18; 15():1463574. PubMed ID: 39290704
    [Abstract] [Full Text] [Related]

  • 14. Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma.
    Cai Z, He C, Zhao C, Lin X.
    Front Oncol; 2021 Apr 18; 11():611118. PubMed ID: 33868997
    [Abstract] [Full Text] [Related]

  • 15. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B, Dai H, Yang J, Zhang G, Wen C, Xiang X, Lin R, Huang Y.
    Curr Cancer Drug Targets; 2023 Apr 18; 23(7):564-571. PubMed ID: 36790005
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhao R, Zhou J, Miao Z, Xiong X, Wei W, Li S, Guo R.
    Front Immunol; 2024 Apr 18; 15():1397827. PubMed ID: 38799453
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.